Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

Infant mortality in the U.S. has increased by 7% since the 2022 Dobbs v. Jackson U.S. Supreme Court decision overturned the ...

Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, according to a entry.

Apple has been ranked as Fortune's Most Admired Company for the 18th consecutive year. The Fortune rankings are based on a survey of ...

The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S . Shareholders who purchased shares of NVO ...

A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...

But generally speaking, investors can have confidence in mega-cap stocks with a dominant position within their industry. As Silicon Valley entrepreneur Peter Thiel once wrote, "Competition is for ...

Ozempic has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic ...

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...

The microbial ecosystems within our mouths may affect our cognitive function as we age, according to a study. Interventions such as prebiotics, including dietary nitrate, have potential for delaying ...

Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy ...

As investors look ahead to data shortly from Veru Inc. with enobosarm, the weight-loss space remains hot, with Novo Nordisk A/S reporting favorable top-line results from a phase Ib/IIa trial ...